nbsp;Sun Pharmaceuticals Industries today announced that the US Food and Drug Administration US FDA has approved SEZABY phenobarbital sodium powder for injection for the treatment of neonatal seizures
With this approval SEZABY becomes the first and only product specifically indicated in the US for the treatment of neonatal seizures in term and preterm infants
SEZABY is expected to be available in the US in Q4FY23
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection It was granted orphan drug designation by the US FDA for the treatment of neonatal seizures
SEZABY was recently licensed by SPARC to Sun Pharma Under the terms of the license agreement SPARC is eligible to receive a milestone payment on approval of SEZABY by the US FDA
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.